Discover.
Launch.
Build.
Transform.

Living our core values.

One of Third Rock’s founding core values is to do the right thing. We believe diversity fuels innovation and are committed to fostering inclusion and diversity in all we do. That's why we are proud to be one of the founding members of the Bioscience & Investor Inclusion Group (BIIG), a coalition created to address diversity, equity and inclusion in the life sciences sector.

Learn More

Abata Therapeutics

Abata Therapeutics is translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with progressive multiple sclerosis (MS) and other severe autoimmune and inflammatory diseases.

Abata Therapeutics

Flare Therapeutics

Flare Therapeutics is opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines.

Flare Therapeutics

bluebird bio

bluebird bio and Bristol Myers Squibb received approval from the U.S. Food and Drug Administration (FDA) for Abecma® (idecabtagene vicleucel) as the first CAR T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma.

bluebird bio

Asher Bio

Asher Bio is pioneering a new approach with for treating cancer and other diseases with cis‑targeted immunotherapies.

Asher Bio

Faze Medicines

Faze is leveraging the groundbreaking new science of biomolecular condensates to develop therapies to slow, halt, or reverse disease pathology.

Faze Medicines

Blueprint Medicines

Blueprint received approval from the U.S. Food and Drug Administration (FDA) for GAVRETO™ (pralsetinib) for the treatment of adult patients with RET fusion-positive non-small cell lung cancer and thyroid cancer. This approval brings forward a new standard of care for a genomically defined population of patients that previously had very limited treatment options.

Blueprint Medicines
14

Years

58

Portfolio Companies

16

Marketed Products

1

Priority: Patients